AHA 2020 - Device Treatment Options for Heart Failure: Appropriate Patient Selection & Identification

November 20, 2020

In this video, Dr. Singh discusses device treatment options available to heart failure patients that remain sympotomatic despite being on guideline directed medical therapy.  CCM® therapy is discussed and the indications for use are outlined including:   NYHA Class III,  EF 25 - 45%, that remain symptomatic despite being treated with Guideline Directed Medical Therapy and that are NOT indicated for Cardiac Resynchronization Therapy.

Login to view comments. Click here to Login